

9-19

A

**NON FEE UTILITY  
Patent Application  
Transmittal**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket Number

STAN201

First Named Inventor

Gerald R. Crabtree et al.

Title

Methods and Compositions for  
Modulating Angiogenesis

Express Mail Label No.

EL852296815US

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

**ADDRESS TO:**Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231☐ Fee Transmittal Form (e.g., PTO/SB/17)

(Submit an original and a duplicate for fee processing)

2. ☒ Applicant claims small entity status.  
See 37 CFR 1.27.3. ☒ Specification Total  
Pages

- Descriptive title of the invention
- Cross Reference to Related Applications
- Statement Regarding Fed sponsored R&D
- Reference to sequence listing, a table, or a computer program listing appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claims(s)
- Abstract of the Disclosure

4. ☒ Drawing(s) (35 U.S.C. 113) Total  
Sheets5. Oath or Declaration Total  
Pages

- a. ☐ Newly executed (original or copy)
- b. ☐ Copy from a prior application (37 CFR 1.63(d))
  - i. ☐ **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s)  
named in the prior application, see 37 CFR  
1.63(d)(2) and 1.33(b)

6. ☒ Application Data Sheet, See 37 CFR 1.767. ☐ CD-ROM or CD-R in duplicate, large table or Computer  
Program (Appendix)8. Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)

- a. ☐ Computer Readable Form (CRF)
- b. Specification Sequence Listing on:
  - i. ☐ CD-Rom or CD-R (2 copies);
  - ii. ☐ Paper
- c. ☐ Statements verifying identity of above copies

**ACCOMPANYING APPLICATION PARTS**

- 9. ☐ Assignment Papers (cover sheet & documents(s))
- 10. ☐ 37 CFR 3.73(b) Statement ☐ Power of  
(when there is an assignee) Attorney
- 11. ☐ English Translation Document (if applicable)
- 12. ☐ Information Disclosure ☐ Copies of IDS  
Statement (IDS)/PTO-1449 Citations
- 13. ☐ Preliminary Amendment
- 14. ☒ Return Receipt Postcard (MPEP 503)  
(should be specifically itemized)
- 15. ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
- 16. ☐ Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i).  
Applicant must attach form PTO/SB/35 or its equivalent
- 17. ☐ Other: \_\_\_\_\_

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment,  
or in an Application Data Sheet under 37 CFR 1.76:☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: \_\_\_\_\_

Prior Application Information:

Examiner \_\_\_\_\_

Group Art Unit: \_\_\_\_\_

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.**Fee Calculation****CLAIMS AS FILED**

For	#Filed	# Allowed	#Extra	Rate	Fee
Total Claims	29	20	9	x	
Indep. Claims	4	3	1	x	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
BASIC FEE					
OTHER FEE (specify purpose) _____					
TOTAL FILING FEE					


**Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)**

19. ☐ Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

***Warning***

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

**20. CORRESPONDENCE ADDRESS**

Name (Print/Type)		Bret E. Field		Registration No.		37,620					
Signature						Date		09-19-2001			
Firm Name		Bozicevic, Field & Francis LLP		Address		200 Middlefield Road, Suite 200					
City		Menlo Park		State		California		zip		94025	
Telephone - Direct Dial		650-833-7705		Fax		650-327-3231					

09560703-091501